Klaus Friese1,2, Bernd Kost1, Aurelia Vattai1, Frederik Marmé3, Christina Kuhn1, Sven Mahner1, Christian Dannecker1, Udo Jeschke1, Sabine Heublein4,5. 1. Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Munich, Germany. 2. Klinik Bad Trissl GmbH, Oberaudorf, Germany. 3. Universitäts-Frauenklinik, Universitäts-Klinikum Heidelberg, Heidelberg, Germany. 4. Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Munich, Germany. sabine.heublein@med.uni-heidelberg.de. 5. Universitäts-Frauenklinik, Universitäts-Klinikum Heidelberg, Heidelberg, Germany. sabine.heublein@med.uni-heidelberg.de.
Abstract
BACKGROUND: Estrogen signalling is transmitted via various receptors and multiple intracellular signalling pathways. Estrogen receptor alpha (ERα)-mediated transcription of target genes has been demonstrated to be closely linked to human papilloma virus (HPV)-induced carcinogenesis in case of cervical cancer. So far, the role of non-genomic estrogen signals in cervical cancer, e.g. transmitted by the G protein-coupled estrogen receptor (GPER) remains to be rather elusive. Today's knowledge on the role of GPER in cervical cancer is sparse and-to the best of our knowledge-GPER has not been investigated in context with clinicopathological parameters or prognosis of cervical cancer. Therefore, the current study investigated whether GPER is expressed in cervical cancer tissue. Further, GPER was correlated to clinicopathological parameters, tissue markers of cervical carcinogenesis and to patient overall and recurrence-free survival. MATERIALS AND METHODS: Cervical cancer tissue was collected from 156 patients during surgery between 1993 and 2002. GPER immunostaining was performed on all the cases and correlated to clinicopathological data. More than half of all patients were diagnosed at advanced stage (FIGO II-IV 93/156; 59.6%) of disease. The large majority of patients presented with tumours of intermediate or high grade (G2-3 140/152, 92.1%). 22 cervical cancer-related deaths (22/156, 14.1%) were documented during the follow-up period. RESULTS: GPER was detected in various subcellular staining patterns. In 129/156 (82.7%) cases GPER was expressed in the tumour cell cytoplasm (GPERcyt). GPER immunopositivity at the cell membrane (GPERmem) was found in 114/156 (73.1%) cases. While co-occurrence of both membrane and cytoplasmic staining (GPERcyt + GPERmem) was detected in the majority of tissue samples (101/156; 64.7%), only few cases (14/156, 9.0%) were classified as not expressing GPER at all. GPERcyt was positively correlated with tumour grade. Statistical associations of GPER and both p16 and p53 were detected. Finally, immunopositivity of GPERcyt was predictive for favourable overall as well as recurrence-free survival in cervical cancer of early stage (FIGO I). CONCLUSION: This retrospective study reports GPERcyt to be associated with improved overall and recurrence-free survival in early-stage cervical cancer. Further investigations are needed thus to determine whether this observation may be of clinical impact. Interestingly, Raloxifene-a GPER-activating selective estrogen receptor modulator-has recently been demonstrated to be preventive for cervical cancer relapse in mice. Whether this effect is only reliant on raloxifene blocking ERα or may also be related to activation of GPER remains to be determined.
BACKGROUND: Estrogen signalling is transmitted via various receptors and multiple intracellular signalling pathways. Estrogen receptor alpha (ERα)-mediated transcription of target genes has been demonstrated to be closely linked to human papilloma virus (HPV)-induced carcinogenesis in case of cervical cancer. So far, the role of non-genomic estrogen signals in cervical cancer, e.g. transmitted by the G protein-coupled estrogen receptor (GPER) remains to be rather elusive. Today's knowledge on the role of GPER in cervical cancer is sparse and-to the best of our knowledge-GPER has not been investigated in context with clinicopathological parameters or prognosis of cervical cancer. Therefore, the current study investigated whether GPER is expressed in cervical cancer tissue. Further, GPER was correlated to clinicopathological parameters, tissue markers of cervical carcinogenesis and to patient overall and recurrence-free survival. MATERIALS AND METHODS:Cervical cancer tissue was collected from 156 patients during surgery between 1993 and 2002. GPER immunostaining was performed on all the cases and correlated to clinicopathological data. More than half of all patients were diagnosed at advanced stage (FIGO II-IV 93/156; 59.6%) of disease. The large majority of patients presented with tumours of intermediate or high grade (G2-3 140/152, 92.1%). 22 cervical cancer-related deaths (22/156, 14.1%) were documented during the follow-up period. RESULTS:GPER was detected in various subcellular staining patterns. In 129/156 (82.7%) cases GPER was expressed in the tumour cell cytoplasm (GPERcyt). GPER immunopositivity at the cell membrane (GPERmem) was found in 114/156 (73.1%) cases. While co-occurrence of both membrane and cytoplasmic staining (GPERcyt + GPERmem) was detected in the majority of tissue samples (101/156; 64.7%), only few cases (14/156, 9.0%) were classified as not expressing GPER at all. GPERcyt was positively correlated with tumour grade. Statistical associations of GPER and both p16 and p53 were detected. Finally, immunopositivity of GPERcyt was predictive for favourable overall as well as recurrence-free survival in cervical cancer of early stage (FIGO I). CONCLUSION: This retrospective study reports GPERcyt to be associated with improved overall and recurrence-free survival in early-stage cervical cancer. Further investigations are needed thus to determine whether this observation may be of clinical impact. Interestingly, Raloxifene-a GPER-activating selective estrogen receptor modulator-has recently been demonstrated to be preventive for cervical cancer relapse in mice. Whether this effect is only reliant on raloxifene blocking ERα or may also be related to activation of GPER remains to be determined.
Authors: W Kedzia; A Goździcka-Józefiak; A Kwaśniewska; M Schmidt; R Miturski; M Spaczyński Journal: Eur J Gynaecol Oncol Date: 2000 Impact factor: 0.196
Authors: Victor Moreno; F Xavier Bosch; Nubia Muñoz; Chris J L M Meijer; Keerti V Shah; Jan M M Walboomers; Rolando Herrero; Silvia Franceschi Journal: Lancet Date: 2002-03-30 Impact factor: 79.321
Authors: Darius Dian; Wolfgang Janni; Christina Kuhn; Doris Mayr; Uwe Karsten; Ioannis Mylonas; Klaus Friese; Udo Jeschke Journal: Onkologie Date: 2009-04-20
Authors: Johan A den Boon; Dohun Pyeon; Sophia S Wang; Mark Horswill; Mark Schiffman; Mark Sherman; Rosemary E Zuna; Zhishi Wang; Stephen M Hewitt; Rachel Pearson; Meghan Schott; Lisa Chung; Qiuling He; Paul Lambert; Joan Walker; Michael A Newton; Nicolas Wentzensen; Paul Ahlquist Journal: Proc Natl Acad Sci U S A Date: 2015-06-08 Impact factor: 11.205
Authors: Sabine Heublein; Klaus Friese; Bernd Kost; Frederik Marmé; Christina Kuhn; Sven Mahner; Christian Dannecker; Doris Mayr; Udo Jeschke; Aurelia Vattai Journal: J Cancer Res Clin Oncol Date: 2018-07-30 Impact factor: 4.553
Authors: Sreejata Chatterjee; Sa Do Kang; Samina Alam; Anna C Salzberg; Janice Milici; Sjoerd H van der Burg; Willard Freeman; Craig Meyers Journal: J Virol Date: 2019-08-13 Impact factor: 5.103
Authors: Sebastian Dietlmeier; Yao Ye; Christina Kuhn; Aurelia Vattai; Theresa Vilsmaier; Lennard Schröder; Bernd P Kost; Julia Gallwas; Udo Jeschke; Sven Mahner; Helene Hildegard Heidegger Journal: Sci Rep Date: 2020-01-24 Impact factor: 4.379
Authors: Wiktor Szewczuk; Oksana Szewczuk; Krzysztof Czajkowski; Bartłomiej Grala; Andrzej Semczuk Journal: J Int Med Res Date: 2019-12-23 Impact factor: 1.671
Authors: Daniel Beilner; Christina Kuhn; Bernd P Kost; Julia Jückstock; Doris Mayr; Elisa Schmoeckel; Christian Dannecker; Sven Mahner; Udo Jeschke; Helene Hildegard Heidegger Journal: J Cancer Res Clin Oncol Date: 2020-07-28 Impact factor: 4.553
Authors: Inocencia Guadalupe Ramírez-López; Adrián Ramírez de Arellano; Luis Felipe Jave-Suárez; Christian David Hernández-Silva; Mariel García-Chagollan; Jorge Hernández-Bello; Edgar I Lopez-Pulido; José Macias-Barragan; Margarita Montoya-Buelna; José Francisco Muñoz-Valle; Ana Laura Pereira-Suárez Journal: Cancer Cell Int Date: 2019-09-02 Impact factor: 5.722
Authors: Christian David Hernández-Silva; Julio César Villegas-Pineda; Ana Laura Pereira-Suárez Journal: Front Endocrinol (Lausanne) Date: 2020-08-20 Impact factor: 5.555